customerservices@hrhealthcare.co.uk

Covid-19 Update

+44 (0)1482 631606

Woulgan

Bioactive beta-glucan gel

Woulgan® Bioactive Beta-Glucan Gel is a treatment for both acute and chronic wounds where wound healing is slow, or is anticipated to heal slower than normal or is at high risk of becoming stalled.

Woulgan has a unique formulation with gel properties and beta-glucan which reactivates stalled healing and accelerates the healing process1,2.

FEATURES

Biotec Betaglucans

Product Benefits

Product features
  • Provides an optimal moist wound-healing environment
  • Re-hydrates necrotic tissue
  • Aids in autolytic debridement
  • Promotes angiogenesis, cell proliferation and wound contraction

SHOW REFERENCES

  1. www.clinicaltrials.gov ID number: NCT 00288392, https://woulgan.com/about/science-behind-woulgan/.
  2. Five model studies using Woulgan in wound healing in diabetic mice. Studies performed by a contract research laboratory for Biotec BetaGlucans.

Clinical Evidence

Author(s)

Title

Publication

Wilde, K.

Use of Woulgan in neuropathic and vascular complex wounds

Wounds UK, 2019, poster

Woodrow, T.

Successful use of an immunomodulator, Bioactive βeta-glucans, to progress a diabetic foot open amputation wound to final closure post negative pressure wound therapy: A case study.

Wound Care Today, 2019, Poster

Woulgan Made Easy

Wounds UK, 2018, 14(5)

Hunt, S,D.

A clinical observation evaluation of bioactive soluble beta-glucan gel compared with standard care

Journal of Wound Care, 2018, 27(9)

King, B., Barrett, S. and Cutting, K.F.

Clinical evaluation of a bioactive beta-glucan gel in the treatment of ‘hard-to-heal’ wounds

Journal of Wound Care, 2017, 26(2)

Welch, D.

A clinical evaluation of Woulgan Biogel in the management of non-infected diabetic foot ulcerations

The Diabetic Foot Journal, 2017, 20(1)

Cutting, K.

Health economics of a bioactive beta-glucan gel

Wounds UK, 2016, poster

Cutting, K.

The nature of beta-glucans – and the role in wound care of a novel bioactive beta-glucan gel: Woulgan

Wounds UK, 2016, poster

Fitzgerald, R.

The clinical and patient experience of using a bioactive beta-glucan gel on a hard-to-heal wound

Wounds UK, 2016, poster

Hepworth, L.

Two case studies to demonstrate the use of an innovative bioactive beta-glucan product for the treatment of stalled wounds

Wounds UK, 2016, poster

Welch, D.

A clinical evaluation of Woulgan in the management of non infected diabetic foot ulcerations

Wounds UK, 2016, poster

Overfield, J.

The use of Woulgan to heal a chronic leg ulceration

Wounds UK, 2016, poster

Svetlana, N. Zykova, et al.

Macrophage stimulating agent soluble yeast β-1,3/1,6-glucan as a topical treatment of diabetic foot and leg ulcers: A randomized, double blind, placebo-controlled phase II study

Journal of Diabetes Investigation, 2014, 5(4)

[1] www.clinicaltrials.gov ID number: NCT 00288392, https://woulgan.com/about/science-behind-woulgan/.3091 WCT Woulgan abstract poster_v2d
[2] Five model studies using Woulgan in wound healing in diabetic mice. Studies performed by a contract research laboratory for Biotec BetaGlucans.


Author

Title

Publication

Link

Wilde, K.

Use of Woulgan in neuropathic and vascular complex wounds

Wounds UK, 2019, poster

Woulgan Made Easy

Wounds UK, 2018, 14(5)

Hunt, S,D.

A clinical observation evaluation of bioactive soluble beta-glucan gel compared with standard care

Journal of Wound Care, 2018, 27(9)

Cutting, K.

Health economics of a bioactive beta-glucan gel

Wounds UK, 2016, poster

Cutting, K.

The nature of beta-glucans – and the role in wound care of a novel bioactive beta-glucan gel: Woulgan

Wounds UK, 2016, poster

Fitzgerald, R.

The clinical and patient experience of using a bioactive beta-glucan gel on a hard-to-heal wound

Wounds UK, 2016, poster

Hepworth, L.

Two case studies to demonstrate the use of an innovative bioactive beta-glucan product for the treatment of stalled wounds

Wounds UK, 2016, poster

King, B., Barrett, S. and Cutting, K.F.

Clinical evaluation of a bioactive beta-glucan gel in the treatment of ‘hard-to-heal’ wounds

Journal of Wound Care, 2017, 26(2)

Overfield, J.

The use of Woulgan to heal a chronic leg ulceration

Wounds UK, 2016, poster

Svetlana, N. Zykova, et al.

Macrophage stimulating agent soluble yeast β-1,3/1,6-glucan as a topical treatment of diabetic foot and leg ulcers: A randomized, double blind, placebo-controlled phase II study

Journal of Diabetes Investigation, 2014, 5(4)

Welch, D.

A clinical evaluation of Woulgan in the management of non infected diabetic foot ulcerations

Wounds UK, 2016, poster

Indications

Woulgan is indicated for use in stalled, dry or low to medium-exuding partial- or full-thickness wounds:

  • Diabetic foot uclers
  • Leg ulcers (any aetiology)
  • Pressure ulcers
  • Graft and donor sites
  • Open surgical wounds
  • Partial-thickness burns
  • Abrasions and lacerations

Time is precious when it comes to wound healing. To avoid chronic development of wounds, patient suffering, extra time and costs needed for dressing changes, you should intervene early with your treatment plans. But, how can you tell if the wound is healing appropriately or too slowly? Try using the wound calculator and find out!


Applying Woulgan*


Woulgan should be applied to a prepared wound bed twice weekly and covered with a suitable secondary dressing.

Woulgan is indicated for use in stalled, dry or low to medium-exuding partial- or full-thickness wounds:

  • Cleanse wound according to local protocol
  • Debride if required
  • If required protect the wound edges
  • Cover the wound surface with a thin layer of Woulgan
  • Apply a suitable secondary dressing of choice and fixate
  • Apply compression or offloading if indicated

You can view the Woulgan user guide here 

View our How to apply video below;

*See product insert leaflet for full instructions for use.


Ordering Details

Description Size Piece per box Product code PIP code NHS code
Woulgan 4g 4 WGA04EA001 406-4192 ELZ867

[1] www.clinicaltrials.gov ID number: NCT 00288392, https://woulgan.com/about/science-behind-woulgan/.
[2] Five model studies using Woulgan in wound healing in diabetic mice. Studies performed by a contract research laboratory for Biotec BetaGlucans.

Item

Size/Pices per box

Product Code

PIP Code

NHS Code

Woulgan®

4g/4

WGA04EA001

406-4192

ELZ867

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Youtube
Consent to display content from Youtube
Vimeo
Consent to display content from Vimeo
Google Maps
Consent to display content from Google
Spotify
Consent to display content from Spotify
Sound Cloud
Consent to display content from Sound